About SPC-15 SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA's ...

Entero Therapeutics, Inc. (Nasdaq: ENTO) ("Entero” or the "Company”), a clinical-stage biopharmaceutical company specializing ...

SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA’s streamlined ...

This announcement is based on a press release statement from Silo Pharma. With a current ratio of 7.9, the company maintains strong liquidity to fund its development pipeline, though analysts tracked ...

Professor Gareth Sanger Research achievements have include the proposal that a novel receptor mediated the ability of 5-HT to increase gastrointestinal motility, later named by others as the 5-HT4 ...

Cisapride is a 5-HT4 agonist and accelerates gastric emptying of solids ... which were used to reduce vomiting symptoms through blocking dopamine type-2 (D2) receptor (dopamine antagonists), 5-HT3 ...

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

What if you could detect allergens even better, so that before you even put something in your mouth, you knew whether it was dangerous? And what if frogs could help you do it?

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.